NCT06512350 Identifying Patterns in the Breath of Individuals With Breast Cancer
| NCT ID | NCT06512350 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Breathe BioMedical Inc |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,175 participants |
| Start Date | 2025-02-25 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,175 participants in total. It began in 2025-02-25 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Researchers will compare the breath profiles of women with breast cancer and those without to determine whether there are disease-specific patterns that can be leveraged to facilitate breast cancer detection. Women with mammogram-confirmed breast tissue density undergoing standard-of-care breast cancer screening will be invited to participate. Those who provide informed consent will provide one breath sample and fill out a questionnaire about their medical history with help from the research coordinators. Breath samples will be collected prior to standard of care biopsy or MRI, and patients will be stratified into the case or control group based on their test results. The primary goal of this project is to use exhaled alveolar breath and the subsequent spectral data produced by Breathe BioMedical's cavity ring-down spectrometer to further develop Breathe BioMedical's technology and machine learning algorithms to determine the feasibility of detecting breast cancer in women aged 40 to 74. Secondarily, this project aims to identify patterns of VOCs that are either over- or under-represented in participants with breast cancer when compared to the breath profiles of participants without breast cancer. This project will also assess performance characteristics of the technology (e.g. sensitivity, specificity, false negative rate, and false positive rate) including subgroup analyses. This project aims to understand intra-subject variability by exploring differences in breath signatures before and after definitive management of breast cancer, including surgical resection.
Eligibility Criteria
Inclusion Criteria: * Female (sex as assigned at birth); * Aged 40 - 74 years; * Mammography confirmed breast tissue density (BI-RADS density score of A, B, C or D); * Scheduled for standard of care biopsy or MRI; * Fluent in language of consent (English, Spanish, or French); * Ability to give informed consent; * Able to provide a breath sample. Exclusion Criteria: * Prior history of breast cancer; * Previous surgical biopsy or surgical excision of breast cancer in the past six months; * History of cancer (except basal cell or squamous cell carcinoma of the skin) in the past year; * Acute respiratory infection and/or symptoms in the past seven days; * MRI BI-RADS 3 undergoing active surveillance (MRI requiring six-month follow-up). * Pregnant or become pregnant during the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06512350 clinical trial?
This trial is open to female participants only, aged 40 Years or older, up to 74 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06512350 currently recruiting?
Yes, NCT06512350 is actively recruiting participants. Contact the research team at sandra.veenstra@breathebiomedical.com for enrollment information.
Where is the NCT06512350 trial being conducted?
This trial is being conducted at Washington D.C., United States, Jacksonville, United States, Durham, United States, Pittsburgh, United States and 1 additional location.
Who is sponsoring the NCT06512350 clinical trial?
NCT06512350 is sponsored by Breathe BioMedical Inc. The trial plans to enroll 5,175 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.